# Mild Cognitive Impairment in Parkinson's Disease

> **NCT01519271** · PHASE4 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 28 (actual)

## Conditions studied

- Parkinson's Disease
- Mild Cognitive Impairment

## Interventions

- **DRUG:** Exelon Patch (rivastigmine transdermal system)
- **DRUG:** Placebo Patches

## Key facts

- **NCT ID:** NCT01519271
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01519271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01519271, "Mild Cognitive Impairment in Parkinson's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01519271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*